Titre : Tumeurs hormonodépendantes

Tumeurs hormonodépendantes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Calbindin 2
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Tumeurs hormonodépendantes : Questions médicales les plus fréquentes", "headline": "Tumeurs hormonodépendantes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Tumeurs hormonodépendantes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-19", "dateModified": "2025-04-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Tumeurs hormonodépendantes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Tumeurs", "url": "https://questionsmedicales.fr/mesh/D009369", "about": { "@type": "MedicalCondition", "name": "Tumeurs", "code": { "@type": "MedicalCode", "code": "D009369", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04" } } }, "about": { "@type": "MedicalCondition", "name": "Tumeurs hormonodépendantes", "alternateName": "Neoplasms, Hormone-Dependent", "code": { "@type": "MedicalCode", "code": "D009376", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Yasuhiro Miki", "url": "https://questionsmedicales.fr/author/Yasuhiro%20Miki", "affiliation": { "@type": "Organization", "name": "Department of Disaster Obstetrics and Gynecology, International Research Institute of Disaster Science (IRIDes), Tohoku University, Sendai, Japan." } }, { "@type": "Person", "name": "Hironobu Sasano", "url": "https://questionsmedicales.fr/author/Hironobu%20Sasano", "affiliation": { "@type": "Organization", "name": "Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan." } }, { "@type": "Person", "name": "Olivier Mansier", "url": "https://questionsmedicales.fr/author/Olivier%20Mansier", "affiliation": { "@type": "Organization", "name": "INSERM U1218, ACTION, Université de Bordeaux, UFR Sciences de la Vie et de la Santé, 33000 Bordeaux, France." } }, { "@type": "Person", "name": "Eric Lippert", "url": "https://questionsmedicales.fr/author/Eric%20Lippert", "affiliation": { "@type": "Organization", "name": "CHRU Brest, Laboratoire d'Hématologie, 29200 Brest, France." } }, { "@type": "Person", "name": "Aleix Prat", "url": "https://questionsmedicales.fr/author/Aleix%20Prat", "affiliation": { "@type": "Organization", "name": "Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain; SOLTI cooperative group, Barcelona, Spain; Institute of Oncology (IOB)-Hospital Quirónsalud, Barcelona, Spain; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA; Department of Medicine, University of Barcelona, Barcelona, Spain. Electronic address: alprat@clinic.cat." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.", "datePublished": "2022-10-14", "url": "https://questionsmedicales.fr/article/36240245", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0275936" } }, { "@type": "ScholarlyArticle", "name": "Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.", "datePublished": "2023-06-19", "url": "https://questionsmedicales.fr/article/37337638", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/cyt.13265" } }, { "@type": "ScholarlyArticle", "name": "Utility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology.", "datePublished": "2022-10-19", "url": "https://questionsmedicales.fr/article/36259232", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cam4.5353" } }, { "@type": "ScholarlyArticle", "name": "Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations.", "datePublished": "2023-02-20", "url": "https://questionsmedicales.fr/article/36808895", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1759-7714.14827" } }, { "@type": "ScholarlyArticle", "name": "RhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma.", "datePublished": "2022-11-02", "url": "https://questionsmedicales.fr/article/36323745", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-20334-0" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Tumeurs", "item": "https://questionsmedicales.fr/mesh/D009369" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs hormonodépendantes", "item": "https://questionsmedicales.fr/mesh/D009376" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Tumeurs hormonodépendantes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Tumeurs hormonodépendantes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Tumeurs hormonodépendantes", "description": "Comment diagnostiquer une tumeur hormonodépendante ?\nQuels tests hormonaux sont utilisés ?\nLes marqueurs tumoraux sont-ils utiles ?\nQuelle imagerie est recommandée ?\nLes antécédents familiaux sont-ils pris en compte ?", "url": "https://questionsmedicales.fr/mesh/D009376?mesh_terms=Calbindin+2&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Tumeurs hormonodépendantes", "description": "Quels sont les symptômes courants ?\nComment les symptômes varient-ils selon le type ?\nLes changements de poids sont-ils un symptôme ?\nLes saignements anormaux sont-ils fréquents ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?", "url": "https://questionsmedicales.fr/mesh/D009376?mesh_terms=Calbindin+2&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Tumeurs hormonodépendantes", "description": "Peut-on prévenir les tumeurs hormonodépendantes ?\nLe dépistage est-il recommandé ?\nL'alimentation joue-t-elle un rôle ?\nL'exercice physique est-il bénéfique ?\nLes hormones de substitution sont-elles sûres ?", "url": "https://questionsmedicales.fr/mesh/D009376?mesh_terms=Calbindin+2&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Tumeurs hormonodépendantes", "description": "Quels traitements sont disponibles ?\nQu'est-ce que l'hormonothérapie ?\nLa chimiothérapie est-elle efficace ?\nLa radiothérapie est-elle courante ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D009376?mesh_terms=Calbindin+2&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Tumeurs hormonodépendantes", "description": "Quelles complications peuvent survenir ?\nLes métastases sont-elles possibles ?\nLes effets secondaires des traitements sont-ils fréquents ?\nComment gérer la douleur liée aux tumeurs ?\nLes complications psychologiques sont-elles courantes ?", "url": "https://questionsmedicales.fr/mesh/D009376?mesh_terms=Calbindin+2&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Tumeurs hormonodépendantes", "description": "Quels sont les principaux facteurs de risque ?\nLe tabagisme influence-t-il le risque ?\nL'alimentation affecte-t-elle le risque ?\nLes traitements hormonaux antérieurs sont-ils un risque ?\nL'exposition à des produits chimiques est-elle un facteur ?", "url": "https://questionsmedicales.fr/mesh/D009376?mesh_terms=Calbindin+2&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une tumeur hormonodépendante ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des examens d'imagerie, des biopsies et des tests hormonaux." } }, { "@type": "Question", "name": "Quels tests hormonaux sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests mesurant les niveaux d'œstrogènes, de progestérone ou de testostérone sont effectués." } }, { "@type": "Question", "name": "Les marqueurs tumoraux sont-ils utiles ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des marqueurs comme le CA 15-3 ou le PSA peuvent aider au diagnostic." } }, { "@type": "Question", "name": "Quelle imagerie est recommandée ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'échographie, la mammographie ou l'IRM sont souvent utilisées pour visualiser les tumeurs." } }, { "@type": "Question", "name": "Les antécédents familiaux sont-ils pris en compte ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancers hormonodépendants augmentent le risque." } }, { "@type": "Question", "name": "Quels sont les symptômes courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des masses, des douleurs, des changements hormonaux et des saignements." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon le type ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes dépendent du type de tumeur, par exemple, des douleurs mammaires pour le cancer du sein." } }, { "@type": "Question", "name": "Les changements de poids sont-ils un symptôme ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des changements de poids peuvent survenir en raison de déséquilibres hormonaux." } }, { "@type": "Question", "name": "Les saignements anormaux sont-ils fréquents ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des saignements anormaux peuvent indiquer une tumeur hormonodépendante, surtout gynécologique." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être similaires à ceux d'autres affections, rendant le diagnostic difficile." } }, { "@type": "Question", "name": "Peut-on prévenir les tumeurs hormonodépendantes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mesures comme un mode de vie sain peuvent réduire le risque, mais pas toutes." } }, { "@type": "Question", "name": "Le dépistage est-il recommandé ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage régulier peut aider à détecter les tumeurs à un stade précoce." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut influencer le risque de développer certaines tumeurs hormonodépendantes." } }, { "@type": "Question", "name": "L'exercice physique est-il bénéfique ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut réduire le risque de certains cancers hormonodépendants." } }, { "@type": "Question", "name": "Les hormones de substitution sont-elles sûres ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent augmenter le risque de certains cancers, nécessitant une évaluation prudente." } }, { "@type": "Question", "name": "Quels traitements sont disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la radiothérapie, l'hormonothérapie et la chimiothérapie." } }, { "@type": "Question", "name": "Qu'est-ce que l'hormonothérapie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "L'hormonothérapie bloque ou modifie l'action des hormones pour ralentir la croissance tumorale." } }, { "@type": "Question", "name": "La chimiothérapie est-elle efficace ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être utilisée pour traiter les tumeurs hormonodépendantes avancées ou récurrentes." } }, { "@type": "Question", "name": "La radiothérapie est-elle courante ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est souvent utilisée pour cibler les tumeurs localisées et réduire leur taille." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés en fonction du type de tumeur et des hormones impliquées." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la propagation de la tumeur, des douleurs chroniques et des effets secondaires des traitements." } }, { "@type": "Question", "name": "Les métastases sont-elles possibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tumeurs hormonodépendantes peuvent se propager à d'autres organes, entraînant des métastases." } }, { "@type": "Question", "name": "Les effets secondaires des traitements sont-ils fréquents ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent provoquer des effets secondaires comme la fatigue, les nausées et des changements hormonaux." } }, { "@type": "Question", "name": "Comment gérer la douleur liée aux tumeurs ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion de la douleur peut inclure des médicaments, des thérapies physiques et des approches complémentaires." } }, { "@type": "Question", "name": "Les complications psychologiques sont-elles courantes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'anxiété et la dépression peuvent survenir chez les patients atteints de tumeurs hormonodépendantes." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, les antécédents familiaux, l'obésité et l'exposition hormonale." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est associé à un risque accru de plusieurs cancers hormonodépendants." } }, { "@type": "Question", "name": "L'alimentation affecte-t-elle le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en graisses saturées peut augmenter le risque de certains cancers." } }, { "@type": "Question", "name": "Les traitements hormonaux antérieurs sont-ils un risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements hormonaux antérieurs peuvent augmenter le risque de développer des tumeurs." } }, { "@type": "Question", "name": "L'exposition à des produits chimiques est-elle un facteur ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains produits chimiques peut augmenter le risque de cancers hormonodépendants." } } ] } ] }

Sources (10000 au total)

Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.

Malignant pleural mesothelioma (MPM) is a cancer associated with asbestos exposure and its diagnosis is challenging due to the moderate sensitivities of the available methods. In this regard, miR-103a...

Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.

Traditionally, the diagnosis of pleural mesothelioma is based on histological material. Minimally invasive effusion cytology specimens are an alternative that, like biopsies, require ancillary analyse... IHC for eight different markers was performed on 59 paired formalin-fixed, paraffin-embedded pleural biopsies and pleural effusion cell blocks with mesothelioma. Immunoreactivity in ≥10% of tumour cel... The overall percentage of agreement between the histological epithelioid component in 58 biopsies and paired cell blocks was 93% for calretinin, 98% for CK5, 97% for podoplanin, 90% for WT1, 86% for E... Generally, a high concordance for IHC staining was seen between paired biopsies and pleural effusion cell blocks from mesotheliomas, but the somewhat lower agreement for WT1, EMA, and especially MTAP ...

Utility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology.

Pleural mesothelioma (PM) is typically diagnosed late during the disease. Earlier detection can increase the chance of effective therapy. Recurrent pleural effusions are the earliest symptoms displayi... We evaluated the diagnostic performance of two immunocytochemical dual stains (BerEp4/Calretinin and Desmin/Epithelial Membrane Antigen (EMA)) on 149 ethanol-fixed cytospin preparation as an initial s... Calretinin had 99% specificity and 98% sensitivity for indicating a mesothelial phenotype, while BerEp4 distinguished the adenocarcinoma cases with 98% specificity and 99% sensitivity. EMA displayed 9... Interpretation of the four immunoreactions is improved when performed as dual stains. The dual staining is a useful tool in the initial handling of atypical effusions and guides the subsequent choice ...

A diagnostic approach to paratesticular lesions with tubulopapillary architecture: a series of 16 serous borderline tumors/low-grade serous carcinoma and 14 well-differentiated papillary mesothelial tumors and mesothelioma.

As there is limited literature on paratesticular tumors of müllerian and mesothelial origin, we reviewed archived cases of serous borderline tumors (n = 15), low-grade serous carcinoma (n = 1), well-d...

Laminar-Specific Alterations in Calbindin-Positive Boutons in the Prefrontal Cortex of Subjects With Schizophrenia.

Cognitive deficits in schizophrenia are associated with altered GABA (gamma-aminobutyric acid) neurotransmission in the prefrontal cortex (PFC). GABA neurotransmission requires GABA synthesis by 2 iso... For 20 matched pairs of subjects with schizophrenia and unaffected comparison subjects, PFC tissue sections were immunolabeled for vGAT, CB, GAD67, and GAD65. The density of CB+ GABA boutons and level... Some CB+ GABA boutons contained both GAD65 and GAD67 (GAD65+/GAD67+), whereas others contained only GAD65 (GAD65+) or GAD67 (GAD67+). In schizophrenia, vGAT+/CB+/GAD65+/GAD67+ bouton density was not a... These findings indicate that schizophrenia-associated alterations in the strength of inhibition from CB+ GABA neurons in the PFC differ across cortical layers and bouton classes, suggesting complex co...

Key Roles of CACNA1C/Cav1.2 and CALB1/Calbindin in Prefrontal Neurons Altered in Cognitive Disorders.

The risk of mental disorders is consistently associated with variants in CACNA1C (L-type calcium channel Cav1.2) but it is not known why these channels are critical to cognition, and whether they affe... To examine the molecular mechanisms expressed in layer III pyramidal cells in primate dorsolateral prefrontal cortices.... The design included transcriptomic analyses from human and macaque dorsolateral prefrontal cortex, and connectivity, protein expression, physiology, and cognitive behavior in macaques. The research wa... Outcome measures included transcriptomic signatures of human and macaque pyramidal cells, protein expression and interactions in layer III macaque pyramidal cells using light and electron microscopy, ... Layer III pyramidal cells in dorsolateral prefrontal cortex coexpress a constellation of calcium-related proteins, delineated by CALB1 (calbindin), and high levels of CACNA1C (Cav1.2), GRIN2B (NMDA re... The layer III pyramidal cells in the dorsolateral prefrontal cortex especially vulnerable in cognitive disorders differentially express calbindin and a constellation of calcium-related proteins includ...